Résumé
Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.
| Langue d'origine | English |
|---|---|
| Numéro d'article | 37 |
| Journal | Journal of Biomedical Science |
| Volume | 20 |
| Numéro de publication | 1 |
| DOI | |
| Statut de publication | Published - 2013 |
Note bibliographique
Funding Information:This work was supported by Grants NSC101-2325-B-006-006, NSC101-2321-B-006-002 and NSC101-2321-B-006-031 from the National Science Council, Taiwan, and DOH102-TD-B-111-002 from Multidisciplinary Center of Excellence for Clinical Trial and Research, Department of Health, Taiwan.
ASJC Scopus Subject Areas
- Endocrinology, Diabetes and Metabolism
- Molecular Biology
- Clinical Biochemistry
- Cell Biology
- Biochemistry, medical
- Pharmacology (medical)
ODD de l’ONU
Cette action contribue à la réalisation des objectifs de développement durable suivants
